Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. The event will include virtual one-on-one meetings for registered investors. A live webcast will be available on the company’s website, with a replay accessible two hours post-event for 90 days. Corbus focuses on innovative immunology solutions targeting the immune system and cancer.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported its fourth quarter and year-end 2021 financial results, revealing a significant drop in revenue, totaling $0 for Q4 compared to approximately $658,000 in Q4 2020. The total revenue for 2021 was $882,000, down from $3.9 million in 2020. Operating expenses decreased by $11.5 million in Q4 and $69.9 million for the year, reaching approximately $10 million and $56.9 million, respectively. The company reported a net loss of $10.3 million for Q4 and $45.6 million for 2021. As of year's end, Corbus had $98.3 million in cash, expected to fund operations into Q1 2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachael Brake, Ph.D., as its new Chief Scientific Officer. Dr. Brake joins from Takeda Pharmaceuticals, bringing extensive experience in oncology drug development. She will advance Corbus' pipeline, focusing on TGFβ-targeting therapeutics and the endocannabinoid system. CEO Yuval Cohen emphasized her leadership as essential for the company's growth. Dr. Brake aims to enhance the impact of immuno-oncology therapies, especially with new acquisitions like CRB-601.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) provided updates and financial results for Q3 2021. The company is progressing its anti-integrin mAb program targeting solid tumors, with first patient dosing expected in H1 2023. Lenabasum's Phase 2 study data is anticipated in Q4 2021. Revenue decreased to approximately $97,000 from $1.23 million in 2020, while operating expenses fell to $14 million from $35.2 million due to reduced clinical costs. Corbus reported a net loss of $2.2 million, down significantly from $34.9 million year-over-year. The company holds $108 million in cash, funding operations into Q1 2024.
Corbus Pharmaceuticals Holdings, a leader in immunology, will have its CEO, Yuval Cohen, participate in a fireside chat at the Jefferies London Healthcare Conference from November 16-19, 2021. This event will be both virtual and in-person, giving attendees the opportunity to engage directly.
An audio webcast of the chat will be available on-demand starting November 18, at 8:00 AM GMT for registered attendees. The presentation aims to advance discussions on Corbus's innovative treatments targeting inflammation and fibrosis.
Corbus Pharmaceuticals Holdings (CRBP) reported its Q2 2021 results, noting that the primary endpoint in the Phase 3 DETERMINE study of lenabasum in dermatomyositis was not met, but activity was observed in other areas. The company plans to engage with the FDA to discuss the next steps. CRBP has $114 million in cash, projected to last into Q1 2024. Revenue from awards and licenses decreased to $137,000, while operating expenses fell to $16.8 million, resulting in a net loss of $17.1 million, an improvement from $38.1 million in Q2 2020.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the topline results of its Phase 3 DETERMINE study on lenabasum for treating dermatomyositis. The study failed to meet its primary endpoint of Total Improvement Score (TIS) at Week 28, with lenabasum achieving a mean TIS of 28.3 versus 26.7 in the control group (p = 0.1965). However, nominally significant improvements were noted in subtypes of the disease. Lenabasum was found to be safe and well-tolerated. The findings will be discussed with regulatory authorities as the company looks to explore next steps.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced today the expansion of its pipeline with two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, aimed at inhibiting TGFβ activation. These mAbs, licensed from UCSF and Panorama Research, target integrins associated with fibrotic diseases and certain cancers. Both are expected to enter Phase 1 testing in 2022. With $125 million in cash, Corbus plans to advance up to four programs into clinical development. The total upfront payment for the licensing deals is $2 million, with potential milestone payments reaching $206 million.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced the publication of two abstracts at the EULAR 2021 Virtual Congress, taking place from June 2-5, 2021. The presentations highlight the Phase 3 Trial of lenabasum for treating Diffuse Cutaneous Systemic Sclerosis and a poster on long-term safety and efficacy of lenabasum in Dermatomyositis. Lenabasum is designed to activate the cannabinoid receptor type 2 to address inflammatory and fibrotic diseases. The abstracts will be available post embargo on the Company’s website.
Corbus Pharmaceuticals (CRBP) announced the adjournment of its 2021 Annual Meeting to allow stockholders more time to vote on proposals, particularly Proposal 4, which seeks to double the authorized common stock from 150 million to 300 million shares. Currently, about 85% of votes cast support this proposal, but it requires a majority of outstanding shares for approval. The meeting will reconvene on June 17, 2021, at 9:00 a.m. ET. Corbus focuses on innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, currently being evaluated for chronic inflammatory diseases.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
